Early rehabilitation in sepsis: a prospective randomised controlled trial investigating functional and physiological outcomes The i-PERFORM Trial (Protocol Article) by Kayambu, Geetha et al.
STUDY PROTOCOL Open Access
Early rehabilitation in sepsis: a prospective
randomised controlled trial investigating
functional and physiological outcomes The
i-PERFORM Trial (Protocol Article)
Geetha Kayambu
1*†, Robert J Boots
1,2 and Jennifer D Paratz
1
Abstract
Background: Patients with sepsis syndromes in comparison to general intensive care patients can have worse
outcomes for physical function, quality of life and survival. Early intensive care rehabilitation can improve the
outcome in general Intensive Care Unit (ICU) patients, however no investigations have specifically looked at
patients with sepsis syndromes. The ‘i-PERFORM Trial’ will investigate if early targeted rehabilitation is both safe and
effective in patients with sepsis syndromes admitted to ICU.
Methods/Design: A single-centred blinded randomized controlled trial will be conducted in Brisbane, Australia.
Participants (n = 252) will include those ≥ 18 years, mechanically ventilated for ≥ 48 hours and diagnosed with a
sepsis syndrome. Participants will be randomised to an intervention arm which will undergo an early targeted
rehabilitation program according to the level of arousal, strength and cardiovascular stability and a control group
which will receive normal care.
The primary outcome measures will be physical function tests on discharge from ICU (The Acute Care Index of
Function and The Physical Function ICU Test). Health-related quality of life will be measured using the Short Form-
36 and the psychological component will be tested using The Hospital Anxiety and Depression Scale. Secondary
measures will include inflammatory biomarkers; Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-a,
peripheral blood mitochondrial DNA content and lactate, fat free muscle mass, tissue oxygenation and
microcirculatory flow.
Discussion: The ‘i-PERFORM Trial’ will determine whether early rehabilitation for patients with sepsis is effective at
improving patient outcomes with functional and physiological parameters reflecting long and short-term effects of
early exercise and the safety in its application in critical illness.
Trial Registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000808044
Background
Critical Illness and trauma are the primary sources of
intensive care unit admissions. An estimated 2-11% of
these patients require prolonged stays in the ICU which
accounts for 25-45% of total I C Ud a y s[ 1 ] .S u r v i v o r so f
intensive care, especially those with prolonged admissions,
may exhibit severe psychological and physical problems
[2] and have a lower health-related quality of life up to
one year following discharge from the hospital [3]. Almost
a quarter of these patients are either admitted with or
develop sepsis i.e. a severe, specific inflammatory response
to infection, during the course of their stay in the ICU
with major immediate and long-term effects on morbidity
and mortality [4]. Patients with sepsis can have a worse
outcome both in terms of overall functioning and mortal-
i t yr a t e s[ 5 ] .T h e r ei se v i d e n c et h a ts p e c i f i cd e c r e a s e si n
muscle mass and muscle force occur in sepsis syndromes
caused by a variety of mechanisms [6]. This has major
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as ultimately impact on the availability of ICU and hospital
beds, surgical waiting lists, health costs and society.
Hypothesising that light to moderate exercise can par-
tially reverse this condition without causing harm to cri-
tically ill patients, several exercise trials conducted in
general intensive care patients have indicated positive
findings that early intervention with exercise is able to
prevent critical illness weakness syndromes, loss of mus-
cle mass, decrease duration of mechanical ventilation,
length of hospital and ICU stay and improve overall qual-
ity of life [7]. Specifically however, it is important to
investigate early rehabilitation in patients with sepsis syn-
dromes as the inflammatory process in sepsis can aggra-
vate and accelerate the rate of muscle wasting in addition
to the immobility associated with the disease in its early
stages. It is equally important to ensure that early exer-
cise in sepsis does not result in oxidative stress or cause
substantial tissue injury potentially worsening the inflam-
matory reaction. The physiological reasons for improve-
ment or adverse effects require investigation (Figure 1).
Sepsis Syndrome
Sepsis is a systemic inflammatory response associated
with an infectious insult. It is the leading cause of death
in critically ill patients and is often associated multi
organ failure [8]. The inflammatory cytokines associated
with sepsis such as Interleukin-6 (IL-6), Interleukin-10
(IL-10) and Interleukin-1b (IL-1b) are found to be corre-
lated with the severity of the disease, the evolution of
organ failure as measured by the SOFA score and
mortality [9]. Physiological responses to inflammation as
described in Table 1 in addition to the presence of a sus-
pected or proven infection has been an internationally
accepted definition for “Sepsis” [8,10]. Increasing sepsis
severity correlates with increasing mortality, rising from
25-30% for severe sepsis to 40-70% for septic shock [11].
Systemic Inflammation and Proteolysis
The aggressive inflammatory process that occurs during
sepsis also affects muscle force, muscle mass and ulti-
mately physical function [12,13]. Persistent elevation of
circulating levels of Interleukin-6 (IL-6) have been
known to infiltrate myocytes with inflammatory factors
such as prostaglandins leading to proteolysis, myocyte
degeneration, and muscle atrophy [14]. Tumour Necro-
sis factor-a (TNF-a) overexpression in sepsis is linked
to the development of cachexia [15] through endothelial
dysfunction, leading to myocyte apoptosis, reduction in
skeletal muscle mass, weakness and myopathy. It has
been hypothesised that the prevention of excessive
release of pro-inflammatory cytokines [15], and activa-
tion of proteolytic pathways leading to limitation of
free-radical generation [16] may inhibit the catabolic
skeletal muscle changes in sepsis [17] and thus critical
illness weakness syndromes.
Inflammatory Biomarkers and Exercise
Interleukin-10 (IL-10); an anti-inflammatory cytokine is
thought to inhibit proteolysis [18] while low levels have
been postulated to lead to excessive inflammation and
muscle damage [19]. IL-10 is known to attenuate the
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Figure 1 Impact of delayed ICU rehabilitation in early sepsis. This diagram illustrates the sequential impact of delayed rehabilitation for
patients with sepsis as a result of the inflammatory processes and the detrimental short and long-term outcomes.
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effects may be beneficial in pathology that results from
inflammatory dysregulation such as in sepsis.
A number of studies [20-22] in healthy and other dis-
eased populations; such as in chronic heart failure, have
shown that aerobic and resisted exercise alters pro-
inflammatory cytokines specifically decreasing IL-6 and
TNF-a and increasing IL-10. Simple physical exercises
such as repetitive passive muscle stretches have been
shown to decrease pro-inflammatory cytokine (IL-6),
increase anti-inflammatory cytokine (IL-10) and
improve the IL-10/TNF-a ratio in chronic critically ill
patients [23]. The use of electrical muscle stimulation
on major muscle groups has been shown to attenuate
the production of TNF-a [24]. It is therefore important
to investigate the effect of exercise on IL-10 in sepsis.
Our pilot study tested 20 patients with sepsis syndromes
randomised into a treatment (proactive rehabilitation) and
a control group. The trial demonstrated significant
decreases (-7.2%) in the percentage fat free mass in the
control group with no decreases in the intervention group.
Significant increases in IL-10 (mean difference 12.1 [SE
+/- 2.1], p < 0.01) were found in the treatment group.
Clinically relevant findings from this study indicate early
exercise reduces loss of muscle mass in sepsis [25].
Oxidative stress
Oxygen-derived free radicals play an important role in
the development and progression of disease in critically
ill patients resulting in increases in the level of Reactive
Oxygen Species (ROS) [26] or decreases in antioxidant
defences [27] causing oxidative stress [28]. ROS can play
a pivotal role in stimulating the inflammatory system by
causing an increase in cytokines (e.g. Interleukins and
TNF-a). Both cytokines and ROS can enter the circula-
tion and mediate systemic inflammatory responses
linked with clinical conditions [29] which are inter-
related in causing muscle proteolysis resulting in the
induction of sepsis-induced myopathy [6].
In patients with sepsis, antioxidant depletion has been
found to be associated with mitochondrial dysfunction
where oxidative stress generates bioenergetic failure [30]
which may affect changes in mitochondrial DNA (mtDNA)
quantity [31], as well as increase mutations or deletions.
This has been hypothesised to be part of the mechanism
underlying multiple organ failure and death [32,33].
Oxidative stress also acts as an atrophic stimulus in an
unloaded muscle [34] promoting wasting by modifying
redox-sensitive processes in its muscle fibres such as dur-
ing periods of disuse in locomotor skeletal muscles [35]
and the unloaded diaphragm during prolonged mechani-
cal ventilation [36,37]. Currently, however, there is no
published data on the effects of exercise on oxidative
stress on the critically ill population particularly in sepsis.
Illness Severity
Hyperlactaemia is a marker of illness severity in sepsis
[38,39]. During early sepsis, perturbation of glycolytic
mechanisms can occur. In septic shock, high concentra-
tions of circulating adrenaline can derive large quantities
of lactate out of skeletal muscles, overwhelming lactate
clearance mechanisms with resultant, hyperlactaemia
[40,41]. The effect of light exercise on lactate clearance
mechanisms in early sepsis remains to be investigated.
Microcirculation and Muscle Oxygenation
Sepsis impairs microcirculatory function causing tissue
hypoxia [42]. This, combined with blood flow diversion
from less important tissues to vital organs [43] promotes
decreased muscular oxygen extraction [44]. However,
the use of electrical stimulation [45] on major muscle
groups and a physical exercise rehabilitation program in
chronic heart failure patients [46] have demonstrated
short-term beneficial systemic effects on microcircula-
tion. The effect of early activity on microcirculation in
patients with sepsis should be further investigated.
Early Rehabilitation may Modulate Detrimental Effects of
Sepsis
The roles of pro-inflammatory cytokines, mitochondrial
changes and muscle proteolysis in causing sepsis-
induced myopathy in critically ill patients are
Table 1 Criteria for SIRS and Sepsis syndromes (modified from Dellinger et al [57])
Syndrome Criteria Mortality
Systemic inflammatory response syndrome (SIRS) any
two or more of the following criteria
▪ HR>90 bpm
▪ RR>20/min or PaCO2< 32 mmHg
▪ WCC< 4 × 10
9 cells/L or > 12 × 10
9 cells/L or > 10% immature bands 12,000
▪ T>38°C or <36°C
Sepsis ▪ SIRS + proven infection 15%
Severe sepsis ▪ Sepsis + failure of one or more organs 20%
Septic shock ▪ Severe sepsis + cardiovascular failure despite adequate fluid resuscitation
(usually SABP <90 mmHg or >40 mmHg from baseline)
45%
HR; Heart rate, RR; Respiratory Rate; WCC; White Cell Count; T; Temperature, SIRS; Systemic Inflammatory Response Syndrome, SABP; Systolic Arterial Blood
Pressure.
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that exercise can modulate cytokine levels [47], ROS
production [48] and ATP levels [49] in patients with
sepsis. In conjunction with an early mobility protocol,
ambulation during mechanical ventilation in the early
stages of critical illness is becoming widely practiced
[50-52], especially with interruption of sedation [53-55].
Conservatively, simple passive movements [56] and neu-
romuscular electrical stimulation [45] as a precursor to
active mobilisation can induce microcirculatory changes
that may attenuate the anti-inflammatory effects in early
sepsis.
Overall, early rehabilitation in critical illness seems to
show reduced time on the ventilator, improved quality
of life and reduced hospital and ICU stay [7] but this is
not specific to sepsis. Furthermore, the short-term sys-
temic effects of exercise for ICU patients remain highly
speculative and debatable. The impact of exercise in the
early stages of critical illness on effects such as oxidative
stress and microcirculatory alterations have been unex-
plored and speculated from other populations. Exploring
these physiological factors in response to exercise can
contribute to determining the safety of early rehabilita-
tion in sepsis.
Hypotheses and Aims
The primary research hypothesis of the “i-PERFORM
Trial” is that patients with defined sepsis syndromes [57]
in the ICU who participate in an early targeted rehabilita-
tion program will have improved physical function and
an improved quality of life. The secondary hypotheses is
that there will be systemic effects underlying primary
improvements which will include; increased fat free mass;
decreased pro-inflammatory and increased anti-inflam-
matory cytokines; increased peripheral blood mitochon-
drial DNA content and reduced blood lactate levels; and
improved tissue oxygenation and microcirculation flow.
Methods/Design
Methods and Design
The i-PERFORM Trial is a prospective double blinded
randomised controlled trial (RCT) in patients with sep-
sis syndromes randomised into an early rehabilitation
intervention arm or a control arm during the course of
ICU stay. All outcomes will be measured by a blinded
assessor from the research team. This study is being
conducted in a quaternary level general Intensive Care
Unit at the Royal Brisbane and Women’sH o s p i t a l
(RBWH), Brisbane, Queenslan d ,A u s t r a l i a .T h eH u m a n
Research Ethics Committee at RBWH and the Medical
Research Ethics Committee at The University of
Queensland have approved this study. The study proto-
col is registered with the Australian New Zealand Clini-
cal Trials Registry (ANZCTR). Figure 2 illustrates the
methodology design for this RCT through recommenda-
tions from CONSORT (Consolidated Standards of
Reporting Trials) Statement.
Inclusion Criteria
To be eligible for recruitment in the study, participants
must be aged 18 years and above; ventilated for ≥ 48
hours; diagnosed with a sepsis syndrome or have a high
clinical suspicion of sepsis [57]. Patients with head inju-
ries, burns, spinal injuries, and multiple fractured lower
limbs requiring specific rehabilitation regimes and
patients with septic shock who are unresponsive to max-
imal treatment and those who are moribund or have an
expected mortality within 48 hours will be excluded.
Recruitment, Randomisation and Blinding
Eligible patients will be identified and consent will be
sought by the chief and principal investigators, with next
of kin or substitute decision maker. Participants recruited
will be randomized into control and intervention arms
using computer generated randomization; http://www.
randomization.com/. The randomization sequence will
be generated and re-identifiable serial numbers will be
assigned by a research personnel not involved in the
study. They will be concealed from consent designee
research staff for group allocation to prevent selection
bias and protected by an electronic password. Partici-
pants, substitute decision makers and outcome assessors
will be blinded to group allocation to avoid influence
over treatment effect. Blinding of the treating phy-
siotherapist and health care providers cannot be ensured
due to the nature of the research intervention.
Demographics
Patient demographic information will be collected at base-
line (recruitment) and ICU and hospital discharge and will
include; age, gender, primary reason for readmission to
ICU, Acute Physiological and Chronic Health Evaluation
II (APACHE II)[58], Sequential Organ Failure Assessment
(SOFA) score [59], Charlson Comorbidity Index [60], time
on mechanical ventilation, length of ICU and hospital stay,
readmissions to ICU and 90-day mortality.
Intervention Arm
Participants randomised to the intervention arm of the
trial will undergo a specific targeted rehabilitation pro-
gram prescribed by the treating ICU physiotherapist for
30 minutes, one to two times daily until discharge from
the ICU within 48 hours of the diagnosis of sepsis
(Early Intervention Arm). The rehabilitation program
will comprise of passive or active range of motion exer-
cises, resistive exercises, electrical muscle stimulation to
major muscle groups, leg or arm ergometry, sitting out
of bed, tilt table therapy and ambulation with assistance.
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intervention arm has been carefully planned with con-
sideration for different levels of cardiovascular stability,
ability of the patient to co-operate, and existing evidence
regarding rehabilitation techniques and mobilisation
strategies in intensive care. It will be administered and
progressed by the discretion of the physiotherapist,
according to individual acuity of illness and level of co-
operation as based on the Ramsay sedation score which
will account for the intervention progression stages. If
the patient deteriorates, a lower level of activity will be
given. Table 2 summarises the intervention strategies.
Control Arm
Participants allocated to the control arm will receive
standard ICU care. The participants randomised to this
group will not receive active rehabilitation from the
research team, i.e. will not be given targeted exercises
early in their disease process upon recruitment. However,
they will continue to receive simple and less regular
mobilisation activities from other sources, as part of the
usual ICU care such as sitting out of bed or ambulation
immediately prior to discharge from the unit. The time
involved in these activities and the type of activities per-
formed will be recorded and compared between groups.
Safety and Withdrawal criteria
A safety audit will be completed on patients in the reha-
bilitation group to monitor any adverse events [61] dur-
ing rehabilitation. Data will be gathered from the
patient’s IntelliVue bedside monitor MP70 (Phillips)
every 10 seconds and printed out for 10 minutes prior,
during and post rehabilitation. The intra-arterial line
will be zeroed 10 minutes prior to exercise. A withdra-
wal criterion with a checklist of adverse events will be
used for the clinical decision of withdrawal or modifica-
tion of exercise intervention.
Primary Outcome Measures
All primary outcomes will be measured at baseline
(recruitment) and at ICU discharge and quality of life at
6 months post hospital discharge. The primary outcome
Figure 2 Research methodology sequence diagram. The inclusion criteria are as follows: Age ≥ 18 yrs and remain ventilated for ≥ 48 hours;
present with documented sepsis or high clinical suspicion of sepsis. Patients with head injuries, burns, spinal injuries, and multiple fractured
lower limbs, those with septic shock unresponsive to treatment, moribund or with expected mortality within 48 hours will be excluded.
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and quality of life (long-term effects) of the participants.
Physical function will be measured using the Acute Care
Index of Function (ACIF) and the Physical Function
ICU Test (PFIT).
The ACIF will essentially rate simple physical function
(transfer bed to chair, sit to stand independently) of the
patient on leaving the ICU [62]. The PFIT is a newly
developed clinical tool for testing functional strength
and endurance capacity in ICU patients. It consists of a
battery of tests assessing endurance, muscle strength,
cardiovascular capacity and functional ability which are
domain representative of physical function and specific
for the use of higher functional assessment in the criti-
cally ill [63]. These have been chosen as corresponding
measuring instruments as they have demonstrated relia-
bility, validity and responsiveness in the ICU population
[63,64].
Quality of life will be measured using the Short Form-
36 (SF-36) Health Survey Questionnaire. Information
from the next of kin will be used to provide proxy
scores which have been demonstrated to have good
reliability and validity [65].
The constructs of psychological well being will be
measured using the anxiety subscale of the Hospital
Anxiety and Depression Scale (HADS) as psychological
wellbeing is known to be highly correlated to functional
physical outcomes [66].
Secondary Outcome Measures
The secondary outcome measures will report on the phy-
siological factors (short-term effects) illustrating underly-
ing mechanisms of early intervention undertaken in the
study. Blood samples (8 ml) will be obtained from the
patients’ arterial line, for the analysis of cytokines, blood
lactate and mtDNA levels pre and post intervention dur-
ing the trial. All blood samples taken will be centrifuged
(Spintron GT-25E/LL, Australia) for 15 minutes at 3000
rpm, within 20 minutes of collection. Plasma from the
whole blood for the cytokine analysis and peripheral
blood mononuclear cells (PBMC) forming the buffy coat
pellet for DNA isolation will be stored at -80°C.
Inflammatory Biomarkers
Biomarkers will be measured before intervention and 30
minutes post intervention daily (week 1) and thereafter
twice weekly (till ICU discharge). The acute inflamma-
tory response of early exercise in sepsis will be mea-
sured by changes in levels of pro-inflammatory
cytokines (IL-6 and TNF-a) and anti-inflammatory cyto-
kine (IL-10). IL-6, IL-10 and TNF-a will be measured
Table 2 Intervention Strategies for early targeted rehabilitation for the critically ill.
Ramsay Sedation
Scale
Stages of
exercise
progression
Conditions Type of Intervention Recommended Exercise
Prescription
6-4 Stage 1 Sedated Passive Range of Motion with stretch reflex to upper
and lower limbs
30 Mins/day
Electrical Muscle Stimulation to major muscle groups 30 Mins/day
3-2 Stage 2 Inotropic
Dependence
Active Range of Motion/Lightly resisted with upper and
lower limb
10 Mins × 2/day
Electrical Muscle Stimulation to major muscle groups 30 Mins/day
Sitting up in Bed with assistance as tolerated 30 Mins × 2/day
Sitting on Edge of Bed 10 Mins × 2/day
2 Stage 3 Weight Active Range of Motion/Lightly resisted with upper and
lower limb
10 Mins × 2/day
Bearing Electrical Muscle Stimulation to major muscle groups 30 Mins/day
Muscle Strength Sitting On Edge of Bed 10 Mins × 2/day
Grade < 3 Sitting Out of Bed with assistance 60 Mins × 2/day
Lower Limb Ergometry 15 Mins × 2/day
Tilt Table Therapy 30 Mins/day
2 Stage 4 Weight Active Range of Motion/Lightly resisted with upper and
lower limb
10 Mins × 2/day
Bearing Electrical muscle stimulation to major muscle groups 30 Mins/day
Muscle Strength Sitting On Edge of Bed 10 Mins/day
Grade > 3 Sitting Out of Bed 30 Mins/day
Upper Limb Ergometry (low level resistance) 15 Mins/day
Lower Limb Ergometry 15 Mins × 2/day
Ambulation with assistive device and therapist 30 Mins × 2/day
The Intervention strategies act as a guide for the execution of early exercises for the patients with sepsis syndromes based on the level of alertness according to
the Ramsay Sedation Scale
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from Millipore (Billerica, MA, USA) using a Luminex
100 assay, with inter and intra-assay CV < 7%.
Muscle Mass
Fat free mass will account for muscle mass (lean tissue)
measured at baseline (week 0) and weekly thereafter (till
ICU discharge) using the Multi-Frequency Bioelectrical
Impedance Spectroscopy (BIS) Machine (ImpediMed
SFB7, ImpediMed Ltd, Brisbane, Australia). Measure-
ments will be taken at a standardised time of the day as
practicable for validity [67] and at standardised anatomi-
cal landmarks for reproducibility of results [68]. Pairs of
gel electrodes will be placed on the hand and foot on
the right side of the body with the participant positioned
in supine. ICU monitoring will continue during mea-
surement without interference [69]. An estimate will be
made of the critically ill patients’ fluid balance. Urinary
catheters will be emptied, prior to measurement. If sub-
jects are known to have ascites, a pleural effusion or a
renal replacement therapy, measurements will not be
done. Percentage fat free mass will be measured in tri-
plicate and analysed to reflect if proteolysis had
occurred and resulted in the loss of muscle mass [70].
Oxidative Stress Markers
Oxidative stress will be determined through changes in
mitochondrial DNA levels. Mitochondrial DNA copy
number in the PBMC will be measured by determining
relative amounts of mitochondrial to nuclear DNA
using quantitative real-time PCR. Mitochondrial DNA
(mtDNA) levels in the peripheral blood will be mea-
sured at baseline (week 0) and weekly thereafter (till
ICU discharge). Total DNA from the blood sample will
be extracted from the buffycoat using a DNA Analysis
Kit (Machery Nagel Blood XL, Germany) and mtDNA
quantity will be analysed using SYBR Green Master Mix
Real Time PCR kit (Applied Biosystems, Warrington,
United Kingdom). Triplicate analysis of blood samples
will be conducted and trends of longitudinal increases
in mitochondrial DNA levels will be reported.
Illness Severity
Blood lactate levels will be measured before intervention
and 30 minutes post intervention with arterial blood
using a standard benchtop Arterial Blood Gas Analyser
(ABL 700 Series gas Machines, RADIOMETER, Copen-
hagen, Denmark). Lactate concentration trends will be
used to analyse lactate clearance rates [71] as a marker
of illness severity.
Muscle oxygenation and Microcirculation
Muscle oxygenation and microcirculatory changes will
be measured using the Near Infrared Oxygenation
(NIR0) Monitor and the Orthogonal Polarization Spec-
tral (OPS) Microscan respectively.
Muscle (tissue) oxygenation will be measured pre and
post intervention daily using the NIRO (NIRO-200,
Hamamatsu, Japan) with a probe placed on a peripheral
muscle to detect levels of muscle oxygenation (StO2)
following acute exercise [72]. Muscle oxygen consump-
tion will be further analysed through induced ischemia
and active hyperaemia [73]. A pneumatic cuff will be
placed above the elbow and inflated to 50 mmHg above
the patient’s systolic blood pressure and the occlusion
will be retained for 3 minutes inducing local ischemia.
StO2 will be recorded continuously for 3 minutes before,
during and after arterial occlusion [44].
Improvements in microcirculation following acute
exercise will be measured pre and post intervention ses-
sion once weekly using the OPS MicroScan (Microvision
Medical Inc, Wallingford, PA, USA) with a non-invasive
probe placed in the sub-lingual space to detect func-
tional capillary density and blood flow velocity as indica-
tors of microcirculatory function [74] using video
images. Five video sequences per patient will be graded
by 3 independent observers and assigned a flow velocity
score to each of the 4 quadrants of each image [75].
Capillary density will be calculated using superimposed
calibrated grid of vertical and horizontal lines on the
images of number of small (< 20 μm) vessels crossing
the lines of the grid divided by the total length of the
lines, yielding the number of small vessels per milli-
metre [76]. An average of these 5 readings will be calcu-
lated for discrete capillary density value for each time
point at which imaging was performed.
Confounding Variables
Critical illness neuropathy and myopathy is a possible
feature of critically ill patients. Formal tests to estab-
lish critical illness neuropathy or myopathy can be
painful, invasive, time consuming and expensive [6].
Such formal diagnosis may not implicate any pertinent
findings in this trial. Basic physiotherapy assessment
muscle testing done as part of regular intervention
assessment using the Medical Research Council or
Manual Muscle Test will detect any possible develop-
ment of weakness without requirements for formal
diagnosis and is accepted as configuration of critical
illness polyneuromyopathy [77].
Sample size
Clinically important difference and the standard devia-
tion estimates used in our sample size calculations were
based on a previous clinical trial [64]. Sample size was
calculated using the ACIF [62] for hypothesis testing
w i t hat y p eIe r r o rr a t eo f0 . 0 5a n d0 . 0 2 5w i t hB o n f e r -
roni adjustment and type II error rate of 0.20 (80%
power). A minimum of 35 per group (70 total) is
required to detect a minimum clinical difference (effect
size) of 0.7 for physical functional outcomes which will
yield clinically significant results for the main hypothesis
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after adjusting for attrition or withdrawal rates, partici-
pation refusals and possible death due to sepsis; based
on admission and mortality rates in the RBWH ICU,
126 patients per group (252 in total) will be required.
A smaller number of patients will undergo mtDNA,
tissue oxygenation and microcirculatory measurements
as these will be tested as pilot investigations. To test
these secondary hypotheses, a minimum of 58 per group
is required to detect a minimum clinical difference of
0.8 for clinically significant changes in mitochondrial
DNA [78], a minimum 91 per group is required to
detect a clinical difference of 0.4 and 59 per group is
required to detect a minimum clinical difference of 0.7
for clinically significant changes in tissue oxygenation
[45] and microcirculation [46] respectively, all corrected
for with Bonferroni adjustment of 0.025.
Data Management and Statistical Analysis
A baseline comparison using both student t-tests and
chi-square for equal proportions of demographic data
will be done between groups at enrolment. Data will
be analyzed using SPSS Version 17.0. The distribution,
range of scores and heterogeneity will be examined for
participants in both groups. Mean changes scores,
standard deviations and 95% confidence intervals will
be calculated and specific analysis detailed under each
outcome measure will be performed. Repeated mea-
sures, between/within analysis of variance (ANOVA)
will be performed to investigate for the main effects of
time and group. Post hoc analyses will then be per-
formed to ascertain where the differences occur. A
Bonferroni correction will be used as the post hoc
measure as there are multiple outcome measures. Ana-
lysis will be by both intention-to-treat and per-proto-
col method. Any violations of the protocol will be
noted. Statistical significance will be set at p < 0.05
and p < 0.025(two-tailed). All efforts will be taken to
a v o i dm i s s i n gd a t ab u ti fi to c c u r sac a r r yf o r w a r d
imputation will be done and linear mixed modelling
will be used for overall analysis. Reasons for loss of fol-
low up will be recorded.
Discussion
The i-PERFORM Trial is an original study in investigat-
ing early rehabilitation in patients presenting with sepsis
syndromes. Fully powered to be a larger trial from the
pilot study, this RCT has been modified to include
detailed and intensive interventional measures and
further outcome measures; SF-36, PFIT, blood lactate,
mitochondrial DNA, muscle oxygenation and microcir-
culation dynamics.
Controversies still exist with regards to the implemen-
tation of early exercise in critically ill patients despite
growing evidence in the literature [7,79]. Introducing
early rehabilitation in patients with sepsis syndromes is
challenging and the direct physiological implications are
unknown. Novel findings from the i-PERFORM Trial
involving physiological markers of oxidative stress and
microcirculation will translate better understanding of
the short-term systemic effects of early exercise in criti-
cal illness. The mechanisms and associations between
early exercise and the inflammatory effects of sepsis
explored in this trial will implicate on future rehabilita-
tion management of patients with sepsis in intensive
care units.
Key Messages
￿ The i-PERFORM RCT will determine whether
early targeted rehabilitation will achieve a higher
functional level and an improved quality of life in
patients with sepsis.
￿ Participants in the intervention arm will receive
early, targeted, individualised rehabilitation program
comprising of passive, active and resisted exercises,
electrical stimulation to major lower limb muscles,
sitting out of bed with exercises and tilt-tabling to
improve orthostatic reflexes, ergometry exercises for
upper and lower limbs and ambulation.
￿ Physical functional capacity, quality of life, psycho-
logical wellbeing, inflammatory biomarkers, oxidative
stress markers, illness severity, muscle oxygenation
and microcirculation will be assessed using standard
instruments at specific times before, during and after
exercise sessions.
￿ Short-term systemic findings from early rehabilita-
tion in sepsis will be novel and will translate better
understanding of the acute effects of early exercise
in critical illness.
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